Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 5Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Papillomavirus Infections 2Melanoma 2Hemangioma, Capillary 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Skin Neoplasms 1Sexually Transmitted Diseases 1Precancerous Conditions 1Pigmentation Disorders 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangioma 1HPV 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Carcinoma in Situ 1

Interventions

Imiquimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pigmentation Disorders × Imiquimod × Clear all
NCT00979550 2018-03-22

The Effects of Aldara as an Adjunct to Laser Treatment

University of Kentucky

Phase 2 Terminated
7 enrolled 4 charts

Pigmentation Disorders, Hemangioma, Capillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡